Alzheimer's and Blood Glucose Levels

Bio Conscious Technologies Inc.100 enrolled

Overview

The Alzheimer's and Blood Glucose Levels Study is researching the differences in blood glucose levels between people with and without Mild Cognitive Impairment or Alzheimer's disease with the aim of early detection of Alzheimer's Disease.

This study will collect continuous glucose monitor (CGM) data from participants already using CGMs to better understand the relationship between Alzheimer's Disease and blood glucose levels. This study will use the " Endobits Companion " app for data collection. The Endobits Companion app is freely available for Android and iOS mobile devices, and was designed to keep track of patients diabetes management through a journal and relay this information with their CGM readings to their caring physician.

Study Type

OBSERVATIONAL

Enrollment

100

Conditions

Mild Cognitive Impairment Alzheimer Disease

Eligibility

Sex: ALLMin age: 50 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * For the case group: have been diagnosed with MCI or AD within the past 5 years. * For the control group: have not been diagnosed with MCI or AD or another major dementia disease * Currently using a continuous glucose monitor (CGM). * Willing and able to provide informed consent, and to have their data collected through the Endobits Companion app. If the participant themself is unable to provide informed consent, it will be sought from their primary caregiver. Exclusion Criteria: * Patients younger than 50 years of age. * Patients with a BMI lower than 18 or higher than 35. * Patients with a major psychiatric illness (e.g., major depressive disorder, schizophrenia, bipolar disorder) * Patients diagnosed with another major dementia disease, including vascular dementia, Lewy Body disease, Huntington's disease, Creutzfeldt-Jakob disease, and Parkinson's disease.

Locations (1)

Bio Conscious Technologies Inc.

Vancouver, British Columbia, Canada

RECRUITING

Outcomes

Primary Outcomes

Blood Glucose Levels

All participants will use continuous glucose monitors for the period of the study. The primary outcome is to determine the difference in mean values, variability, and other patterns in blood glucose levels between the case and control groups. As there is no intervention in this study, the difference between the case and control group will be measured over the entire study period.

Time frame: This will be measured throughout the study which is a period of up to 90 days.

Central Contacts

Amir Hayeri, MSc

CONTACT

+1-778-986-3030 amir@bioconscious.tech

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.